enGene, Inc.

Core Business and Therapeutic Focus

The fundamental business of enGene is the discovery, development, and commercialization of a new generation of non-viral gene therapies. Unlike traditional gene therapies that rely on viral vectors, enGene utilizes its proprietary, advanced delivery platform to enable targeted treatment at the site of the disease. The core therapeutic area is initially urological cancers, particularly non-muscle invasive bladder cancer (NMIBC), but the technology is designed for broad application across multiple organ systems, including the lung and gut, addressing a variety of serious diseases. The company aims to provide innovative solutions that reduce treatment burden, improve patient outcomes, and overcome the limitations often associated with viral-based genetic medicines, such as immunogenicity, systemic toxicities, and complex cold-chain logistics.

Products and Services: The DDX Platform

The foundational "service" or technology offered by enGene is its proprietary Dually Derivatized Oligochitosan® (DDX) gene delivery platform. This platform is a breakthrough in localized genetic medicine, designed to safely and efficiently deliver genetic material directly to target cells within mucosal tissues and other organs.

• DDX Platform Mechanics: The DDX platform utilizes a novel, non-viral carrier system based on dually derivatized chitosan. This carrier is engineered to penetrate the protective mucosal lining, facilitating the delivery of a therapeutic cargo into the target cells. Once inside, the genetic material acts as a "blueprint," effectively turning the local cells into "therapeutic production factories" that generate proteins and/or RNAs for a desired local effect.
• Cargo Flexibility and Versatility: A key feature of the DDX platform is its high degree of payload flexibility. It can carry a wide range of nucleic acid payloads, including DNA and various forms of RNA (such as siRNA, shRNA, and lncRNA). This versatility positions the platform for deployment across numerous therapeutic areas and disease mechanisms.
• Manufacturing and Logistics Advantage: The DDX-based therapies are designed to be "off-the-shelf" and do not require the specialized handling or cold-chain storage typical of many viral gene therapies. This simplicity in manufacturing, handling, and administration is intended to make the treatments well-suited for deployment in busy urology or community clinics, thereby increasing patient access and reducing logistical complexity.

Lead Product Candidate and Pipeline

enGene's products are centered on investigational, clinical-stage candidates developed using the DDX platform.

Detalimogene Voraplasmid (previously EG-70)

• Description and Indication: Detalimogene voraplasmid is the company's lead product candidate, an investigational, first-in-class, localized non-viral gene therapy currently being studied for the treatment of non-muscle invasive bladder cancer (NMIBC). Specifically, it targets high-risk NMIBC patients with carcinoma in situ (Cis) who are unresponsive to or naive to treatment with Bacillus Calmette-Guérin (BCG), a complex disease with a high risk of recurrence and progression.
• Mechanism of Action: Detalimogene is designed as an immune-oncology gene therapy. It delivers a genetic blueprint that instructs bladder cells to express a combination of two double-stranded RNAs and the cytokine IL-12. This "one-two punch" mechanism is intended to activate a potent and localized immune response in the bladder, enabling the body to recognize and attack the cancer while minimizing the systemic toxicities often associated with conventional immunotherapies.
• Clinical Status and Designations: Detalimogene is being evaluated in the pivotal LEGEND Clinical Trial. Due to its potential to address serious unmet medical needs in NMIBC, the U.S. Food and Drug Administration (FDA) has granted the therapy both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, which are intended to provide opportunities for expedited development and review.

Pipeline Expansion Programs

Beyond the lead NMIBC program, enGene is actively leveraging the DDX platform to expand its pipeline into new therapeutic areas by engineering non-viral gene delivery to other mucosal tissues.

• Oncology and Immune System Diseases: The company has programs in earlier development, including additional drug candidates such as EG-i08, EG-10, EG-i21, and a Plasmid DNA based PD-L1 gene therapy. These candidates suggest a broader focus on immune system diseases and other neoplasms, continuing to exploit the immune-modulating potential of localized gene delivery.
• Respiratory and Gastrointestinal Indications: DDX is well-positioned for gene delivery to the lung and gut. enGene is actively developing unique genetic medicines for respiratory indications and is evolving its technology to enable applications in several other mucosal tissues, signifying a strategy to apply its non-viral, localized approach to a diverse range of diseases beyond urology.

In summary, enGene, Inc. is a leading biotech entity defined by its innovative DDX non-viral gene delivery platform. The company's focus is on mainstreaming genetic medicine by providing localized, "off-the-shelf" treatments, with its core product, Detalimogene voraplasmid, representing a significant advancement in the treatment of NMIBC and serving as a proof-of-concept for a versatile platform that aims to expand gene therapy into multiple organ systems and therapeutic areas.